Sonnet BioTherapeutics Holdings, Inc. (SONN)

Market Cap	2.57M
Revenue (ttm)	173,303
Net Income (ttm)	-22.59M
Shares Out	3.06M
EPS (ttm)	-64.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137
Open	1.55
Previous Close	1.50
Day's Range	1.44 - 1.57
52-Week Range	1.08 - 36.96
Beta	0.88
Analysts	Strong Buy
Price Target	139.47 (+9,198.62%)
Earnings Date	Dec 18, 2023

About SONN

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. T...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Pankaj Mohan Ph.D.
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: SONN

Financial Performance

In 2022, SONN's revenue was $349,943, a decrease of -27.64% compared to the previous year's $483,626. Losses were -$29.72 million, 19.0% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for SONN stock is "Strong Buy." The 12-month stock price forecast is $139.47, which is an increase of 9,198.62% from the latest price.

Price Target

$139.47

(9,198.62% upside)

Analyst Consensus: Strong Buy